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Vascular disease, either as a direct complication of the disease or developing as an accompanying comorbidity impairs signiﬁcantly
the quality of life of patients with SLE and represents the most frequent cause of death in established lupus. This paper aims to
give an overview of the prevalence of the diﬀerent forms of vasculopathy that can be encountered in a lupus patient, describe their
pathogenesis, and address their impact on disease severity and outcome.
1.Introduction
Vascular disease is frequent in patients with systemic lupus
erythematosus and represents the most frequent cause of
death in established disease. In this context, vasculopathy
can be directly aetiologically implicated in the pathogenesis
of the disease, presenting as an acute/subacute manifestation
of lupus (e.g., antiphospholipid syndrome, lupus vasculitis).
Alternatively, it can develop as an important accompanying
comorbidity (steroid-related atherosclerotic disease), or rep-
resent the synergistic pathogenetic outcome of augmented
atherosclerosis within a proinﬂammatory environment.
This paper aims to give an overview of the prevalence of
the diﬀerent forms of vasculopathy that can be encountered
in a lupus patient, describe their pathogenesis, and address
their impact on disease severity and outcome.
2. Epidemiology
Systemic lupus erythematosus (SLE) is a multiorgan autoim-
mune disease with an increased incidence rate of thrombotic
events (9–37%), occurring at a younger age compared to the
control population [1].
The high rates of reported cardiovascular comorbidity
[2]appeartobelargelyattributedtothesigniﬁcantpredispo-
sition of SLE patients for atherosclerosis and coronary artery
disease (CAD) [3] ;C A Di s5 - 6t i m e sm o r ef r e q u e n ti nS L E
patients when compared to healthy controls, independent of
other coexisting cardiovascular risk factors [4], and repre-
sents the majority of vascular events in SLE patients [5]. This
excessriskisespeciallypronouncedinwomenofyoungerage
(35–44yrs; >50-fold) [6, 7].
Additionally, SLE patients are at a 20% higher risk for
stroke; 3–15% experience a nonfatal thrombotic stroke [8],
its incidence however usually recurrent and associated with a
higher mortality rate than matched controls [9].
The rate of thrombotic events is higher in patients with
disease of recent onset, when compared to patients with
other autoimmune diseases and remains so throughout the
course of the disease [10]; in the LUMINA study, which
included multiethnic SLE patients of recent diagnosis, age,
damageaccrualatenrolment,andantiphospholipidantibod-
ies, as well as the use of higher dosages of glucocorticoids
were associated with a shorter time interval to thrombotic
events [1]. Besides recorded clinical disease, subclinical
involvement is signiﬁcantly increased compared to healthy
individuals, reaching 30% in reported studies [11].
Cardiovascular disease is the most frequent cause of
death in established disease (>8yrs after diagnosis; [12]):
infection and renal involvement attributing for the majority
of cases during the early stages (ﬁrst year of diagnosis).
As mortality rates of SLE patients tend to decrease signif-
icantly over time, and patients’ life expectancy increases,
its prevalence among an aged population becomes more
pronounced, and its relevance gains increasing signiﬁcance
[13].2 Autoimmune Diseases
3. Atherosclerosis in Lupus
Atherosclerotic disease has been detected in lupus patients
from cohort studies in a signiﬁcant proportion of the pop-
ulation (≥30%), even when corrected for all other comor-
bidities [3, 14] .T h ep r e v a l e n c ew a sh i g h e rc o m p a r e dt oc o r -
responding groups, when patients included had previously
been treated with atherogenically predisposing treatments,
such as steroids, or surprisingly, in younger patients (age <
55 years).
Subclinical disease reached levels of 52% and was con-
ﬁrmed with a variety of techniques, such as carotid and
brachial artery Doppler ultrasound, coronary artery angiog-
raphy, and SPECT dual-isotope myocardial perfusion imag-
ing [15].
Why do SLE patients develop more atherosclerosis? For
once, cardiovascular risk factors seem to be more prevalent
among SLE patients: hypertension, diabetes mellitus, seden-
tary lifestyle, hyperlipidemia, hypertriglyceridemia, hyper-
homocysteinemia, and even premature menopause. How-
ever, as mentioned previously, after correcting for all pre-
disposing cardiovascular risk factors, lupus still qualiﬁes
as an independent atherogenic (cardiovascular) risk factor
[10, 16].
The SLE-associated proinﬂammatory cytokine burden
and SLE-related treatments such as corticosteroids, that is,
at a dose >10mg/daily promote atherogenesis. These two
parameters tend to interconnect, as disease of higher inten-
sity and thus higher proinﬂammatory burden qualiﬁes for
the use of corticosteroids in lupus. Patients without previous
history of steroid treatment tend to have more carotid
atherosclerotic plaques, possibly due to less eﬃciently con-
tr olleddiseaseacti vity .H o wev er ,inlupus,aorticstiﬀnessand
increased pulse wave velocity do not always correlate with
proven carotid atherosclerosis [17, 18]. As the pathogenesis
ofthediseaseunravelsandmorepro-andanti-inﬂammatory
(i.e., protective) molecules become identiﬁed and their role
in the course of the disease characterized, associations with
increased aortic stiﬀness (e.g., C-reactive protein, VCAM,
and C3) or vasoprotection (TGFb-1) become established
[19].
4. Antiphospholipid Syndrome
The clinical antiphospholipid syndrome, an autoimmune
syndrome usually developing in the context of systemic
lupus erythematosus, is a condition deﬁned as a pre-
disposition for arterial and/or venous thromboses and/or
recurrent miscarriages or other obstetric emergencies (pre-
mature birth, preeclampsia, etc.) in association with hema-
tologicabnormalitiesandspeciﬁcantibodiestargetedagainst
phospholipid-binding plasma proteins [20]. Indeed, retro-
spective studies in patients with clinical thrombotic events
revealed a higher prevalence of positivity for antiphospho-
lipid antibodies [21]. Thrombosis within the context of
antiphospholipid syndrome may occur even in histologically
normal vessels. However, in the majority of aPL-positive
patients, seropositivity per se does not suﬃce for the devel-
opment of clinical events. Thrombotic events seem to occur
more readily in lupus patients with coexistent atherosclerosis
[22]. Moreover, according to the second-hit hypothesis, a
second trigger event—such as cigarette smoking, oral con-
traceptives, surgical procedures, prolonged immobilization
Deﬁnition Immobilization refers to the process of holding
a joint or bone in place with a splint, cast, or brace. This is
done to prevent an injured area from moving while it heals,
hypertension, or a genetic prothrombotic state increases the
likelihood of an aPL-positive patient developing a vascular
event [23–25].
Recently, the presence of microangiopathy, deﬁned as
capillary microhemorhages, and diagnosed with the aid of
capillaroscopy, has been proposed as an augmentary screen-
ing tool for aPL-seropositive patients who are prone to
develop clinical thrombotic manifestations [26].
5. LivedoidVasculopathy: Thrombotic Disease
and/or Vasculitis?
Besides overt vessel obstruction, vascular disease in lupus,
especially when aﬀecting medium- and small-sized vessels,
may contain both vasculopathic and vasculitic pathophysio-
logic parameters.
Livedoid vasculopathy, a condition which can be ob-
served in patients with systemic lupus erythematosus/anti-
phospholipid syndrome or speciﬁc forms of systemic vas-
culitis (mainly polyarteritis nodosa and cryoglobulinemia),
isassociatedwithchroniculcerationsofthelowerextremities
and characterized by uneven perfusion [27]. Initial isolated
orfocalpetechiaeorpurpuraprogresstoformasymmetrical,
irregular, painful, and recurrent leg ulcers which heal in
the form of atrophic white scars. In lupus in particular,
analogous lesions may also be observed in the upper
extremities (elbows) and seem to be associated with disease
manifestations aﬀecting other systems (e.g., central nervous
system) [28].
The pathogenesis of livedoid vasculopathy has not been
fully elucidated, or rather, cannot be solely attributed to
a particular mechanism, as both hypercoagulable states, as
well as autoimmune diseases, appear to associate with and
contribute to its development [29].
The typical histological ﬁndings show dermal blood
vessel occlusion [30] a diagnosis biochemically strength-
ened by increased prothrombotic markers (prothrombin
gene variations, hyperhomocysteinemia, protein C deﬁ-
ciency, increased activity of plasminogen-activator-inhibitor,
and activated protein C resistance). The histopathological
ﬁndings of intravascular ﬁbrin, segmental hyalinization,
and endothelial proliferation clearly support the throm-
botic parameter of its pathogenesis [31] .T h ep r e s e n c eo f
immunoreactants in the vessel wall and circulating immune
complexes (such as rheumatoid factor) are in favor of its
immunologicalcomponent;theabsencehoweverofﬁbrinoid
necrosis and inﬂammatory inﬁltration of the vessel wall dif-
ferentiate livedoid vasculopathy from true vasculitides. The
cutaneous features as well as nervous system manifestations
(neuropathies or central nervous system involvement) in
patients with livedoid vasculopathy may respond to immu-
nosuppressive treatment.Autoimmune Diseases 3
6.LupusVasculitis
Distinction of inﬂammatory lupus vasculitis from antiphos-
pholipid syndrome, which may present with similar clinical
manifestations, is of major signiﬁcance in terms of clinical
management. Inﬂammatory vascular disease is triggered by
the in situ formation, or the deposition, of immune com-
plexes within the vessel wall.
Vasculitis may manifest in as high as 56% of lupus
patients throughout their life, in contrast to antiphospho-
lipid syndrome which has a prevalence of 15%. Patients with
vasculitisaremainlymaleandtendtobeofyoungerage[32].
Antibodies against endothelial cells have been identiﬁed
as a major endothelial cell cytotoxic eﬀector and have been
implicated in the pathogenesis of several connective tissue
diseases, predominantly vasculitides [33]. More than 80%
of systemic lupus erythematosus patients are positive for
antiendothelial cell antibodies (AECAs) [34, 35]. Antigens
that react with AECAs include heparinlike compounds,
DNA and DNA-histone complexes, ribosome proteins, elon-
gation factor 1a, adenyl cyclase-associated protein, pro-
ﬁlin II, plasminogen activator inhibitor, ﬁbronectin, and
b2-glycoprotein. AECA-endothelial cell interaction attracts
monocyte adhesion and induces secretion of chemoattrac-
tant proteins and cytokines, thus triggering vasculitis.
Besides AECAs, the presence of antineutrophil cyto-
plasmic autoantibodies (ANCAs), mainly associated with
primary systemic vasculitides, has also been reported in 15-
20% of SLE patients [36].
Other forms of SLE-related vasculitis include drug-
induced vasculitis [37] and infection-induced vasculitis [38]
either through direct compromise of the vascular wall by
pathogens, or through antigen-induced autoimmune and
inﬂammatory processes.
7.SLE-AssociatedVascularDisease:
Burden and Outcome
In conclusion, vascular disease appears to be inherent in the
pathogenesis and clinical manifestations of systemic lupus
erythematosus; its severity ranging from mild cutaneous
disease to severe organ dysfunction, such as renal or central
nervous system vasculitis, atherosclerotic cardiovascular or
cerebrovascular events, or catastrophic antiphospholipid
syndrome.
Inlupus,morereadilythanperhapsinanyothersystemic
autoimmune disease, vascular disease may combine, in the
same individual, atherosclerotic, and thrombotic disease
with systemic vasculitis per se, and autoinﬂammatory-driven
degeneration of the vessel wall.
In a histopathological study of autopsied SLE patients,
histological characterization of vessel involvement and size
of aﬀected vessels were associated with the cause of death.
Fibrinoid degeneration, intimal thickening, thrombosis, and
sclerosis were identiﬁed and recorded. The principal man-
ifestations of the disease were found to be associated with
smaller-sized arteries. However, patients with medium-sized
arterial involvement usually presented with more frequent
thrombotic events and exhibited higher morbidity rates than
the rest of the patients [39].
Lifestyle and pharmaceutical prevention measures, regu-
larscreeningforsubclinicaldisease,alertnessforearlyclinical
signs, accurate diﬀerential diagnosis, and targeted treatment
may prove organ- or even life-saving especially in younger
patients with more aggressive disease [40].
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